Enhanced anti-glioblastoma activity of microglia by AAV2-mediated IL-12 through TRAIL and phagocytosis in vitro

Oncology Reports

Volumn 25, Issue 5, 2011, Pages 1373-1380

  Chiu, Tsung Lang ^a,b   Peng, Chih Wen ^a   Wang, Mei Jan ^b,c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

Author keywords

Adeno associated virus; Glioblastoma multiforme; Interleukin 12; Microglia; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; INTERLEUKIN 12; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOVIRUS 2; ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CELL ACTIVATION; CELL ACTIVITY; CELL FUNCTION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE RELEASE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROGLIA; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; GLIOBLASTOMA; HEK293 CELLS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; MICE; MICROGLIA; PHAGOCYTOSIS; RATS; RECEPTORS, DEATH DOMAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79953053268     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1213     Document Type: Article

References (35)

1. Portielje J, Gratama J, van Ojik H, Stoter G and Kruit W: IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 52: 133-144, 2003. (Pubitemid 36384713)
2. Fujiwara H and Hamaoka T: Antitumor and antimetastatic effects of interleukin 12. Cancer Chemoth Pharmacol 38: S22-S26, 1996.
3. Fehniger T, Cooper M and Caligiuri M: Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 13: 169-183, 2002.
4. Dredge K, Marriott J, Todryk S and Dalgleish A: Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 51: 521-531, 2002. (Pubitemid 35232001)
5. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146, 2003.
6. Colombo M and Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168, 2002.
7. Leonard JP, Sherman ML, Fisher GL, et al: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541-2548, 1997. (Pubitemid 27413462)
8. Kowalczuk A, Macdonald R, Amidei C, et al: Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41: 1028-1038, 1997. (Pubitemid 27475463)
9. Daneyemez M, Gezen F, Canakci Z and Kahraman S: Radical surgery and reoperation in supratentorial malignant glial tumors. Minim Invasive Neurosurg 41: 209-213, 1998. (Pubitemid 29039782)
10. Kayama T, Kumabe T, Tominaga T and Yoshimoto T: Prognostic value of complete response after the initial treatment for malignant astrocytoma. Neurol Res 18: 321-324, 1996. (Pubitemid 26292131)
11. Warrington K and Herzog R: Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 119: 571-603, 2006.
12. Foti S, Haberman R, Samulski R and McCown T: Adenoassociated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo. Gene Ther 14: 1534-1536, 2007. (Pubitemid 47570712)
13. Lo W, Qu G, Sferra T, Clark R, Chen R and Johnson P: Adenoassociated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther 10: 201-213, 1999. (Pubitemid 29070634)
14. Flotte T: Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther 11: 805-810, 2004.
15. Aitken M, Moss R, Waltz D, et al: A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 12: 1907-1916, 2001.
16. Kaplitt M, Feigin A, Tang C, et al: Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097-2105, 2007. (Pubitemid 46935946)
17. Mittelbronn M, Dietz K, Schluesener H and Meyermann R: Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol 101: 249-255, 2001. (Pubitemid 32219759)
18. Hanisch U and Kettenmann H: Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387-1394, 2007. (Pubitemid 350014685)
19. Badie B and Schartner J: Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46: 957-962, 2000. (Pubitemid 30198803)
20. Kim S and de Vellis J: Microglia in health and disease. J Neurosci Res 81: 302-313, 2005. (Pubitemid 41359284)
21. Rock RB, Gekker G, Hu S, et al: Role of microglia in central nervous system infections. Clin Microbiol Rev 17: 942-964, 2004. (Pubitemid 39372525)
22. Hussain SF, Yang D, Suki D, Aldape K, Grimm E and Heimberger AB: The role of human glioma-infiltrating microglia/ macrophages in mediating antitumor immune responses. Neurooncology 8: 261-279, 2006. (Pubitemid 46542651)
23. Sliwa M, Markovic D, Gabrusiewicz K, et al: The invasion promoting effect of microglia on glioblastoma cells is inhibited by cyclosporin A. Brain 130: 476-489, 2007. (Pubitemid 46181101)
24. Watters J, Schartner J and Badie B: Microglia function in brain tumors. J Neurosci Res 81: 447-455, 2005.
25. Chiu T, Lin S, Hsieh W and Peng C: AAV2-mediated interleukin-12 in the treatment of malignant brain tumors through activation of NK cells. Int J Oncol 35: 1361-1367, 2009.
26. Wang M, Huang H, Hsieh S, Jeng K and Kuo J: Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J Neuroimmunol 112: 28-34, 2001.
27. Feigin A, Kaplitt MG, Tang C, et al: Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 104: 19559-19564, 2007.
28. Cucchiarini M, Ren X, Perides G and Terwilliger E: Selective gene expression in brain microglia mediated via adeno-associated virus type 2 and type 5 vectors. Gene Ther 10: 657-667, 2003. (Pubitemid 36553611)
29. Shevtsova Z, Malik JMI, Michel U, Bähr M and Kügler S: Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol 90: 53-59, 2005.
30. Wesolowska A, Kwiatkowska A, Slomnicki L, et al: Microglia-derived TGF-beta as an important regulator of glioblastoma invasion-an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene 27: 918-930, 2008. (Pubitemid 351225378)
31. Hussain S, Yang D, Suki D, Grimm E and Heimberger A: Innate immune functions of microglia isolated from human glioma patients. J Transl Med 4: 15, 2006.
32. Huang Y, Erdmann N, Peng H, Zhao Y and Zheng J: The role of TNF related apoptosis-inducing ligand in neurodegenerative diseases. Cell Mol Immunol 2: 113-122, 2005.
33. Aktas O, Schulze-Topphoff U and Zipp F: The role of TRAIL/ TRAIL receptors in central nervous system pathology. Front Biosci 12: 2912-2921, 2007.
34. Gene S, Kizildag S, Gene K, Ates H, Atabey N and Kizyldag S: Interferon gamma and lipopolysaccharide upregulate TNF-related apoptosis-inducing ligand expression in murine microglia. Immunol Lett 85: 271-274, 2003. (Pubitemid 36349031)
35. Johnstone R, Frew A and Smyth M: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798, 2008.